Answers are grounded in this paper and cite their sources.
During the COVID-19 pandemic, conditions for the deterioration of the mental health of a wide range of people at risk were created. The manifestation or exacerbation of mental illness contributes to the spread of COVID-19 and is associated with the frequent development of somatic complications and an unfavorable prognosis. Psychopharmacotherapy in patients with COVID-19 should take into account its effect on respiratory function, possible side effects and inter-drug interactions. The drug that can be recommended for the treatment of depressive and anxiety-depressive symptoms in COVID-19 is a representative of the modern class of antidepressants, multimodal modulators of the serotonin system — trazodone.
No takes yet. Share an insight, caveat, or question.
Maruta et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: